Viking Therapeutics (VKTX) Stock Price, News & Analysis

Company Overview

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. The company’s research programs target conditions including obesity, nonalcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH), dyslipidemia and other disorders involving hormone regulation and metabolism.

Viking’s lead program is VK2735, an investigational dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed in injectable and oral formulations for obesity and related metabolic conditions. Its pipeline has also included VK2809, an orally administered thyroid hormone receptor beta agonist studied for liver and lipid disorders, as well as earlier-stage programs addressing other metabolic and endocrine diseases. The company does not currently market an approved commercial product.

Founded in 2012 and headquartered in San Diego, California, Viking conducts its research and clinical development activities primarily through programs and trials in the United States, while its potential therapies are intended for broader international markets. The company is led by Brian Lian, Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $35.10 to $39.05
• 50-Day Range: $28.99 to $41.65
• 52-Week Range: $24.88 to $43.15
• Volume: 13.56 million shs
• Average Volume: 6.06 million shs
• Market Capitalization: $4.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $99.67
• Consensus Rating: Moderate Buy

Viking Therapeutics Stock Analysis - MarketRank™

Viking Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 360th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Viking Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Viking Therapeutics has a consensus price target of $99.67, representing about 180.3% upside from its current price of $35.56.

Amount of Analyst Coverage

Viking Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Viking Therapeutics are expected to grow in the coming year, from ($4.47) to ($4.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Viking Therapeutics is -7.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viking Therapeutics is -7.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Viking Therapeutics has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.44% of the float of Viking Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Viking Therapeutics has a short interest ratio ("days to cover") of 12.32, which indicates bearish sentiment.

Change versus previous month

Short interest in Viking Therapeutics has recently increased by 1.79%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Viking Therapeutics does not currently pay a dividend.

Dividend Growth

Viking Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.39

News Sentiment

Viking Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 59 news articles for Viking Therapeutics this week, compared to 9 articles on an average week.

Search Interest

34 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 162% compared to the previous 30 days.

MarketBeat Follows

23 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 156% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Viking Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,268,442.00 in company stock.

Percentage Held by Insiders

5.30% of the stock of Viking Therapeutics is held by insiders.

Percentage Held by Institutions

76.03% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VKTX
• CIK: 1607678
• Web: www.vikingtherapeutics.com
• Phone: (858) 704-4660
• Fax: N/A
• Employees: 65
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Viking Therapeutics: $99.67
• High Price Target: $125.00
• Low Price Target: $65.00
• Potential Upside/Downside: +180.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$359.64 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -94.56%
• Return on Assets: -82.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.72
• Quick Ratio: 4.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.65 per share
• Price / Book: 6.29

Miscellaneous

• Outstanding Shares: 116,650,000
• Free Float: 110,470,000
• Market Cap: $4.15 billion
• Optionable: Optionable
• Beta: 0.69